Abstract:Purpose: A prospective Phase I/II dose escalation study was conducted to determine the maximum tolerated dose (MTD) in three-dimensional conformal radiation therapy (3D-CRT) for non-small-cell lung cancer (NSCLC).Methods and Materials: MTD would be reached via a dose escalation study. After 42 Gy/21 fractions, 4.2 weeks by conventional fractionated irradiation through anteroposterior/posteroanterior fields, the 3D-CRT technique was used as boost. The planned total dose escalation depended on lung volume irradiated. According to the percentage of lung volume receiving >20 Gy, the patients were divided into three subgroups (i.e., <25%, 25%-37%, and >37%). The scheduled dose escalation began with 69 Gy and continued to 78 Gy. The boost doses were delivered at 3 Gy per fraction, once per day, five fractions per week. Each dose level includes 5 patients. Besides radiotherapy, all patients received neoadjuvant and adjuvant chemotherapy with MVP regimen (Mitomycin, Vindesine, cis-platium). The criterion for stopping further dose escalation was greater than or equal to20% of patients with greater than or equal toRTOG Grade 3 radiation pneumonitis.Results: Between June 1999 and February 2001, 50 patients had been enrolled in this study, including 4 with Stage II disease, 31 with Stage IIIa disease, and 15 with Stage IIIb disease. The dose escalation plan has been completed. All subgroups reached the highest predetermined dose levels (i.e., 78 Gy for the <25% subgroup, 78 Gy for the 25-37% subgroup, and 75 Gy for the >37% subgroup). Although none of the subgroups developed more than 20% of greater than or equal toGrade 3 acute pneumonitis, dose escalation was terminated because long-term follow-up was needed to observe late complications. Median follow-up time (NUT) for the entire group was 18 months (6-37 months). The most common acute complication was esophagitis in 56% of patients with RTOG Grade 1-2, and in 4% with Grade 3. Acute radiation pneumonitis developed in 36% of patients with RTOG Grade 1-2. Only 1 patient had Grade 3 pneumonitis, which was in the 25-37% subgroup at 75 Gy. The hematopoietic toxicity appeared in 58% of patients with Grade 1-2, and 8% with Grade 3. As to late complications, only 30% of patients developed pulmonary fibrosis of RTOG Grade 1-2. The median survival time for the entire group was 18 months. Two-year overall survival, locoregional progression-free rate, and distant metastasis rate were 44%, 40%, and 41%, respectively.Conclusion: Although MFT was 18 months, it had not yet been declared because a longer follow-up was needed to observe the late complications. The 2-year overall survival of 44% was very encouraging and implied that 3D-CRT combined with chemotherapy would improve the outcome for locally advanced NSCLC. (C) 2003 Elsevier Inc.

Clinical Study on the Effect of Hypofractionated Three -Dimensional Conformal Radiation Therapy in the Treatment of Non -Small Cell Lung Cancer

Study of Late Course Three Dimensional-Conformal Radiotherapy Combined with Chemotherapy for 29 Cases with Recurrent Rectal Cancer.

Late Course Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy for Stage Ⅲ Non-Small Cell Lung Cancer

Three Dimensional-conformal Radiotherapy Combined Concurrent Chemotherapy with Vinorelbine and Cisplatin for Stage Ⅲ Non-small Cell Lung Cancer

Feasibility and Efficacy of Helical Intensity-Modulated Radiotherapy for Stage III Non-Small Cell Lung Cancer in Comparison with Conventionally Fractionated 3D-CRT.

Clinical Study of Late-Course Three-Dimensional Conformal Radiotherapy for Esophageal Carcinoma

Three-Dimensional Conformal Radiation Therapy For Non-Small-Cell Lung Cancer: A Phase I/Ii Dose Escalation Clinical Trial

A Phase II Trial of Accelerated Hypofractionated Three-Dimensional Conformal Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer

A prospective, multicenter, phase II clinical study of three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small-cell lung cancer-PPRA-RTOG003

Prognosis of Three Dimensional Conformal Radiotherapy of Locally Advanced Non-small Cell Lung Cancer with Involved-field

The impact of tumor regression on the dose distribution of the three dimensional conformal radiotherapy for non-small cell lung cancer

The Curative Effect Observation of Treating Local Advanced Non-Small Cell Lung Cancer with 3D-CRT

Outcomes of Image-Guided Moderately Hypofractionated Radiotherapy for Stage III Non-Small-Cell Lung Cancer

Efficacy Fi Cacy and Toxicity of Moderately Hypofractionated Radiation Therapy with Helical TomoTherapy Versus Conventional Radiation Therapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer Receiving Concurrent Chemotherapy: A Multicenter, Randomized Phase 3 Trial

Three-dimensional Conformal Radiotherapy(3-Dcrt)combined with Radiofrequency Hyperthermia for Locally Advanced Non-Small-cell Lung Cancer(lansclc)

Hypofractionated Stereotactic Radiation Therapy for Advanced Non-Small Cell Lung Cancer: Report on Clinical Outcome and Toxicity

Effect of 3-Dimensional Interstitial High-Dose-Rate Brachytherapy with Regional Metastatic Lymph Node Intensity-Modulated Radiation Therapy in Locally Advanced Peripheral Non-Small Cell Lung Cancer: 5-Year Follow-up of a Phase 2 Clinical Trial.

Three dimensional-conformal radiotherapy combined with gemcitabine chemotherapy for locally advanced non-small cell lung cancer

A Prospective,multicenter,phase Ⅱclinical Study of Three-Dimensionalradiotherapy with Concurrent Chemotherapy for Stage IV Non-Small-cell Lung Cancer-the Impact of Different Pathological Types on Survival (PPRA-RTOG003)

Application of Hypofractionated Conformal Radiotherapy in Non-Small Cell Lung Cancer

Safety and Efficacy of Hypofractionated Radiotherapy and Concurrent Chemotherapy in Unresectable Stage III Non-Small-Cell Lung Cancer